Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its Zepbound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback